ScholarGate
アシスタント

手法を比較

選択した手法を並べて確認できます。異なる行はハイライト表示されます。

リスク調整型第I相臨床試験×適応型第I相臨床試験×
分野疫学疫学
系統Process / pipelineProcess / pipeline
提唱年1990s–2000s1990 (model-based adaptive era); rule-based designs from the 1970s–1980s
提唱者Evolved from the Continual Reassessment Method (O'Quigley et al., 1990) extended with patient-level risk covariatesO'Quigley, Pepe, and Fisher (CRM); earlier rule-based 3+3 designs pre-date it
種類Interventional clinical trial designAdaptive clinical trial design
原典Iasonos, A., Wilton, A. S., & Gonen, M. (2008). A review of stochastic dose-finding methods. Statistics in Medicine, 27(25), 5031–5046. link ↗O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. DOI ↗
別名risk-stratified Phase I trial, risk-adaptive dose-escalation study, covariate-adjusted Phase I study, risk-based dose-finding trialadaptive dose-escalation trial, adaptive dose-finding study, model-based adaptive Phase I design
関連51
概要A risk-adjusted Phase I clinical trial is a first-in-human or dose-finding study that explicitly incorporates patient-level risk covariates — such as organ function, prior therapy, or genetic markers — into the dose-escalation model. Rather than treating all enrolled participants as homogeneous, the design accounts for individual differences in tolerance, allowing the recommended dose to vary by risk stratum. This approach is especially common in oncology, where patients with impaired renal function or heavily pre-treated disease may tolerate lower doses than the broader population.An adaptive Phase I clinical trial is a first-in-human or early-phase dose-finding study that continuously updates the recommended dose after each patient cohort using a prespecified statistical model, rather than following a fixed rule. The goal is to identify the maximum tolerated dose (MTD) or the recommended Phase II dose (RP2D) efficiently while minimising exposure of participants to sub-therapeutic or toxic doses. Adaptive designs — most notably the Continual Reassessment Method (CRM) — replace or augment traditional rule-based designs such as the 3+3 schema.
ScholarGateデータセット
  1. v1
  2. 2 出典
  3. PUBLISHED
  1. v1
  2. 2 出典
  3. PUBLISHED

検索へ スライドをダウンロード

ScholarGate手法を比較: Risk-adjusted Phase I clinical trial · Adaptive Phase I Clinical Trial. 2026-06-20に以下より取得 https://scholargate.app/ja/compare